Skip to main content
Premium Trial:

Request an Annual Quote

Flemish Government Provides $2.5M to Biocartis to Develop Cancer Tests

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

The funding is for a two-year period, during which Biocartis will develop tests to run on its fully automated system. The tests will be directed at the detection of known, validated oncogenes "and allow for more targeted treatment of certain cancers," Biocartis said.

The company plans to focus on skin, colon, and lung cancer. It will also seek to develop tests to simultaneously detect "dozens of parameters" for use on its Dynamic Multi-Analyte Technology, or DMAT, platform, a multiplex detection platform for the research market.

The system was launched in December. At the time the company announced the completion of a $45 million Series D financing round.

"Oncology is our company’s primary focus for the development of diagnostic tests," Erwin Sablon, head of Applied Assay Development for Biocartis, said in a statement. "This grant will speed up the development of a broad range of clinically relevant tests that will help make cancer treatment more efficient and personalized as well as improve survival rates for patients."

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.